189 related articles for article (PubMed ID: 34908850)
1. Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant
Zhang F; Zhong J; Ding H; Liao G
Infect Drug Resist; 2021; 14():5165-5174. PubMed ID: 34908850
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection.
Xiao S; Fu Q; Miao Y; Zhao M; Lu S; Xu J; Zhao W
Front Microbiol; 2023; 14():1198926. PubMed ID: 37664109
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
[No Abstract] [Full Text] [Related]
12. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
16. Effects of preservative fluid associated possible donor-derived carbapenem-resistant Klebsiella Pneumoniae infection on kidney transplantation recipients.
Zhang F; Zhong J; Ding H; Liao G
BMC Nephrol; 2022 Mar; 23(1):101. PubMed ID: 35287599
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
Infection; 2024 Jun; ():. PubMed ID: 38884857
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study.
Lin J; Zhang L; Zhou M; Tian X; Chen J; Lu M; Liu Z
Infect Dis Ther; 2023 Aug; 12(8):2165-2177. PubMed ID: 37653121
[TBL] [Abstract][Full Text] [Related]
19. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant
Abu Jaber AMR; Basgut B; Hawan AA; Al Shehri AA; AlKahtani SA; Ahmed NJ; Abdi A
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]